BioSpace News Archive

Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results for the fourth quarter and fiscal year 2023, which include the consolidated financial results for GRAIL.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22, at 4:30 p.m. ET to discuss fourth quarter and full-year 2023 financial results and provide a general business update.

Curis, Inc. reported its business update and financial results for the quarter ended December 31, 2023.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth-quarter and full year 2023 financial results on Thursday, February 22, 2024.

Harmony Biosciences Holdings, Inc. announced that it will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024, before the open of the U.S. financial markets.

Halberd Corporation’s Traumatic Brain Injury mitigating nasal spray testing protocols at Mississippi State University were approved by the Institutional Animal Care and Use Committee.

Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device, has been granted regulatory approval by the Sultanate of Oman’s Ministry of Health.

Allurion Technologies, Inc. today announced that it will be participating in the BTIG Snowbird Conference taking place on Monday, February 12 through Wednesday, February 14, 2024 in Snowbird.

BIOTRONIK is proud to introduce the Micro Rx™ catheter, a novel rapid exchange microcatheter developed to easily enhance guidewire support during percutaneous coronary interventions.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced it has completed enrollment of its Phase 2 HELIOS trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) for the treatment of Wolfram syndrome (WS), a rare genetic disease that typically results in neurodegeneration and premature death, which has no known cure.